Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Earnings for Lipella Pharmaceuticals Inc. (LIPO)
Earnings in 2023 (TTM): $-4,618,965
According to Lipella Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-4,618,965. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Lipella Pharmaceuticals Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-4,618,965 | $-4,618,965 |
| 2022 | $-2,597,692 | $-2,596,059 |
| 2021 | $-1,865,473 | $-1,872,203 |
| 2020 | $-61,656 | $-66,450 |
| 2019 | $-61,848 | $-61,848 |